50-nm Gate Schottky Source/Drain p-MOSFETs With a SiGe Channel

Abstract-We propose new SiGe channel p-MOSFETs with germano-silicide Schottky source/drains (S/Ds). The Schottky barrier-height (SBH) for SiGe is expected to be low enough to improve the injection of carriers into the SiGe channel and, as a result, current drivability is also expected to improve. In this letter, we demonstrate the proposed Schottky S/D p-MOSFETs down to a 50-nm gate-length. The drain current and transconductance are 339 A m and 285 S m at GS = DS = 1 5 V, respectively. By increasing the Ge content in the SiGe channel from 30% to 35%, the drive current and transconductance can be improved up to 23% and 18%, respectively. This is partly due to the lower barrier-height for strained Si 0 65 Ge 0 35 channel than those for strained Si 0 7 Ge 0 3 channel device and partly due to the lower effective mass of the holes

Role of Dlg5/lp-dlg, a Membrane-Associated Guanylate Kinase Family Protein, in Epithelial-Mesenchymal Transition in LLc-PK1 Renal Epithelial Cells

Discs large homolog 5 (Dlg5) is a member of the membrane-associated guanylate kinase adaptor family of proteins, some of which are involved in the regulation of epithelial-to-mesenchymal transition (EMT). Dlg5 has been described as a susceptibility gene for Crohn's disease; however, the physiological function of Dlg5 is unknown. We show here that transforming growth factor-β (TGF-β)-induced EMT suppresses Dlg5 expression in LLc-PK1 cells. Depletion of Dlg5 expression by knockdown promoted the expression of the mesenchymal marker proteins, fibronectin and α-smooth muscle actin, and suppressed the expression of E-cadherin. In addition, activation of JNK and p38, which are stimulated by TGF-β, was enhanced by Dlg5 depletion. Furthermore, inhibition of the TGF-β receptor suppressed the effects of Dlg5 depletion. These observations suggest that Dlg5 is involved in the regulation of TGF-βreceptor-dependent signals and EMT

進行卵巣癌(3期)における治療法と予後

雑誌掲載版初回治療を施行した3期上皮性卵巣癌患者73例の治療法と予後を検討した。初回手術に26症例で腫瘍の完全摘出が可能であった。2cm以下の残存腫瘍を認めたもの6例,2cm以上の残存腫瘍を認めたもの19例,試験開腹に終わったものが22例であった。この22例のうち9例が化学療法後の2度目の手術で腫瘍を完全摘出した。腫瘍の完全摘出が予後に改善に関与しており,その時期は初回手術に限る必要はない。漿液性嚢胞腺癌,類内膜型腺癌の場合はCAPまたはCPをレジメとするNeo adjuvant Chemotherapyにより腫瘍の完全摘出が可能となり得

〔妊娠初期の胎芽・胎児の管理〕Early clinical pregnancyの時期 正常GSとblighted ovum

出版社